Novartis QVA149 Phase III study meets primary endpoint in reducing exacerbations in COPD patients, filing in EU and Japan by end of year
30 August 2012 | By Novartis
SPARK met its primary endpoint...
List view / Grid view
30 August 2012 | By Novartis
SPARK met its primary endpoint...
29 August 2012 | By Novartis
Novartis welcomed its annual International Biotechnology Leadership Camp...
28 August 2012 | By Novartis
Novartis received approval today from the European Commission for Jakavi®...
26 August 2012 | By Novartis
Novartis announced results from the Phase II PARAMOUNT study...
15 August 2012 | By Novartis
Results of two Phase III studies...
6 August 2012 | By Novartis
Collaboration to study CAR technology...
30 July 2012 | By Novartis
The EC has approved Afinitor®...
20 July 2012 | By Novartis
The US FDA has approved Afinitor® tablets...
22 June 2012 | By Novartis
CHMP has adopted a positive opinion for Seebri® Breezhaler®...
22 June 2012 | By Novartis
Positive opinion for Afinitor® tablets...
11 June 2012 | By Novartis
New long-term data for Gilenya®...
6 June 2012 | By Novartis
New data announced from two trials...
31 May 2012 | By Novartis
Novartis will showcase the clinical progress of multiple marketed and pipeline compounds...
17 May 2012 | By Novartis
Results from pivotal Phase III GLOW2 study...
10 May 2012 | By Novartis
Research on Lucentis® is highlighted in more than 200 abstracts this week at the 2012 ARVO annual meeting....